August 8, 2018 / 12:43 PM / 4 months ago

Drugmaker Mylan considering strategic alternatives

Aug 8 (Reuters) - Drugmaker Mylan NV said on Wednesday it was evaluating a wide range of alternatives, sending its shares down nearly 5 percent before the bell.

Mylan's board has formed a strategic review committee but has not set a timetable for evaluation of the alternatives.

The company also reported an 87 percent slump in second-quarter profit.

Reporting by Saumya Sibi Joseph and Tamara Mathias in Bengaluru

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below